Dengue vaccine Qdenga available privately at R$390-490 per dose; public campaign targets youth 10-14

Japanese pharmaceutical dominance in tropical disease prevention expands Brazil's healthcare dependency on foreign biotech. Unequal vaccine access by income reinforces socioeconomic health disparities within Brazil, potentially affecting regional stability as dengue spreads to previously unaffected areas like southern Brazil.

Similar to polio vaccination campaigns in developing nations during Cold War era, vaccine availability stratification reflects broader patterns of unequal health infrastructure and pharmaceutical market dynamics in emerging economies.

Private consumers face significant out-of-pocket costs (R$780-980 per person for full vaccination course), creating equity gaps. Public sector vaccination limited to youth 10-14 in select cities, leaving older populations and other age groups without subsidized access. Households in high-incidence regions (Center-West, South) face greater disease risk and vaccination cost burden.

Government may need to: (1) expand public vaccination program beyond current age/geographic restrictions given rising dengue cases; (2) negotiate bulk pricing with Takeda to reduce private sector costs; (3) consider vaccine subsidy programs for vulnerable populations; (4) address supply chain constraints limiting public campaign scope; (5) evaluate cost-benefit of broader immunization strategy versus current targeted approach.